Related Experiment Videos
Intensely cytotoxic anthracycline prodrugs: glucuronides
1Department of Clinical Investigation, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Journal of Medicinal Chemistry
|December 24, 1997
Summary
New anthracycline glucuronide prodrugs release potent anticancer agents in the presence of beta-glucuronidase. These prodrugs show significant potential for cancer therapy, especially with enzyme-targeting strategies.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Therapeutics
Background:
- Previous work established doxorubicin prodrugs releasing cytotoxic agents via carboxylate esterases.
- Structurally related beta-glucuronide prodrugs were synthesized for activation by beta-glucuronidases.
Purpose of the Study:
- To synthesize and evaluate novel anthracycline beta-glucuronide prodrugs.
- To assess the efficacy and activation of these prodrugs in cancer cells.
Main Methods:
- Reductive condensation of daunomycin/doxorubicin with a protected glucuronate derivative.
- Cleavage of protective groups to yield final prodrugs.
- Enzymatic hydrolysis studies using Escherichia coli beta-glucuronidase and cytotoxicity assays.
Main Results:
- Daunomycin glucuronide prodrugs were obtained in good yields, while doxorubicin analogues yielded low amounts.
- The daunomycin glucuronide prodrug (6a) showed a half-life of 30 hours in buffer and 1.7 hours with beta-glucuronidase.
- Prodrug 6a demonstrated a 10,000-fold increase in toxicity to melanoma cells in the presence of the enzyme.
Conclusions:
- Anthracycline glucuronide prodrugs are effectively activated by beta-glucuronidase to release potent cytotoxic metabolites.
- These prodrugs hold therapeutic promise as standalone agents or in combination with enzyme-targeting strategies like ADEPT and GDEPT.